Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients

Tae Hoon Roh, Hun Ho Park, Seok Gu Kang, Ju Hyung Moon, Eui Hyun Kim, Chang Ki Hong, Sung Soo Ahn, Hye Jin Choi, Jaeho Cho, Se Hoon Kim, Seung Koo Lee, Dong Seok Kim, Sun Ho Kim, Chang Ok Suh, Kyu Sung Lee, Jong Hee Chang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution. Outcomes were retrospectively reviewed in 252 consecutive patients with newly diagnosed GBM who underwent surgery followed by CCRT with TMZ at the authors' institution between 2005 and 2013. At initial operation, 126 (50.0%), 55 (21.8%), 45 (17.9%), and 26 (10.3%) patients underwent gross total resection (GTR), subtotal resection, partial resection (PR), and biopsy, respectively. Their median overall survival (OS) was 20.8 months (95% confidence interval [CI] 17.7-23.9 months) and their median progression-free survival was 12.7 months (95% CI 11.2-14.2 months). The O 6-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 78 (34.1%) of the 229 patients assayed, and an isocitrate dehydrogenase 1 mutation was detected in 7 (6.6%) of the 106 patients analyzed. Univariate analyses showed that patient age, involvement of eloquent areas, involvement of the subventricular zone, presence of leptomeningeal seeding, Karnofsky Performance Status, extent of resection (EOR), MGMT promoter methylation, and presence of an oligodendroglioma component were prognostic of OS. Multivariate analysis showed that age, involvement of eloquent areas, presence of leptomeningeal seeding, EOR, and MGMT promoter methylation were significantly predictive of survival. OS in patients with GBM who undergo surgery followed by CCRT with TMZ is enhanced by complete resection. Other factors significantly prognostic of OS include that age, involvement of eloquent areas, presence of leptomeningeal seeding, and MGMT promoter methylation.

Original languageEnglish
Article numbere7422
JournalMedicine (United States)
Volume96
Issue number27
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

temozolomide
Chemoradiotherapy
Glioblastoma
Methyltransferases
Survival
Methylation
DNA
O(6)-Methylguanine-DNA Methyltransferase
Confidence Intervals
Oligodendroglioma
Karnofsky Performance Status
Isocitrate Dehydrogenase
Lateral Ventricles
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Roh, Tae Hoon ; Park, Hun Ho ; Kang, Seok Gu ; Moon, Ju Hyung ; Kim, Eui Hyun ; Hong, Chang Ki ; Ahn, Sung Soo ; Choi, Hye Jin ; Cho, Jaeho ; Kim, Se Hoon ; Lee, Seung Koo ; Kim, Dong Seok ; Kim, Sun Ho ; Suh, Chang Ok ; Lee, Kyu Sung ; Chang, Jong Hee. / Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. In: Medicine (United States). 2017 ; Vol. 96, No. 27.
@article{e8be0745d0bc4132b69c516293f23635,
title = "Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients",
abstract = "The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution. Outcomes were retrospectively reviewed in 252 consecutive patients with newly diagnosed GBM who underwent surgery followed by CCRT with TMZ at the authors' institution between 2005 and 2013. At initial operation, 126 (50.0{\%}), 55 (21.8{\%}), 45 (17.9{\%}), and 26 (10.3{\%}) patients underwent gross total resection (GTR), subtotal resection, partial resection (PR), and biopsy, respectively. Their median overall survival (OS) was 20.8 months (95{\%} confidence interval [CI] 17.7-23.9 months) and their median progression-free survival was 12.7 months (95{\%} CI 11.2-14.2 months). The O 6-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 78 (34.1{\%}) of the 229 patients assayed, and an isocitrate dehydrogenase 1 mutation was detected in 7 (6.6{\%}) of the 106 patients analyzed. Univariate analyses showed that patient age, involvement of eloquent areas, involvement of the subventricular zone, presence of leptomeningeal seeding, Karnofsky Performance Status, extent of resection (EOR), MGMT promoter methylation, and presence of an oligodendroglioma component were prognostic of OS. Multivariate analysis showed that age, involvement of eloquent areas, presence of leptomeningeal seeding, EOR, and MGMT promoter methylation were significantly predictive of survival. OS in patients with GBM who undergo surgery followed by CCRT with TMZ is enhanced by complete resection. Other factors significantly prognostic of OS include that age, involvement of eloquent areas, presence of leptomeningeal seeding, and MGMT promoter methylation.",
author = "Roh, {Tae Hoon} and Park, {Hun Ho} and Kang, {Seok Gu} and Moon, {Ju Hyung} and Kim, {Eui Hyun} and Hong, {Chang Ki} and Ahn, {Sung Soo} and Choi, {Hye Jin} and Jaeho Cho and Kim, {Se Hoon} and Lee, {Seung Koo} and Kim, {Dong Seok} and Kim, {Sun Ho} and Suh, {Chang Ok} and Lee, {Kyu Sung} and Chang, {Jong Hee}",
year = "2017",
month = "7",
day = "1",
doi = "10.1097/MD.0000000000007422",
language = "English",
volume = "96",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "27",

}

Roh, TH, Park, HH, Kang, SG, Moon, JH, Kim, EH, Hong, CK, Ahn, SS, Choi, HJ, Cho, J, Kim, SH, Lee, SK, Kim, DS, Kim, SH, Suh, CO, Lee, KS & Chang, JH 2017, 'Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients', Medicine (United States), vol. 96, no. 27, e7422. https://doi.org/10.1097/MD.0000000000007422

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. / Roh, Tae Hoon; Park, Hun Ho; Kang, Seok Gu; Moon, Ju Hyung; Kim, Eui Hyun; Hong, Chang Ki; Ahn, Sung Soo; Choi, Hye Jin; Cho, Jaeho; Kim, Se Hoon; Lee, Seung Koo; Kim, Dong Seok; Kim, Sun Ho; Suh, Chang Ok; Lee, Kyu Sung; Chang, Jong Hee.

In: Medicine (United States), Vol. 96, No. 27, e7422, 01.07.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients

AU - Roh, Tae Hoon

AU - Park, Hun Ho

AU - Kang, Seok Gu

AU - Moon, Ju Hyung

AU - Kim, Eui Hyun

AU - Hong, Chang Ki

AU - Ahn, Sung Soo

AU - Choi, Hye Jin

AU - Cho, Jaeho

AU - Kim, Se Hoon

AU - Lee, Seung Koo

AU - Kim, Dong Seok

AU - Kim, Sun Ho

AU - Suh, Chang Ok

AU - Lee, Kyu Sung

AU - Chang, Jong Hee

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution. Outcomes were retrospectively reviewed in 252 consecutive patients with newly diagnosed GBM who underwent surgery followed by CCRT with TMZ at the authors' institution between 2005 and 2013. At initial operation, 126 (50.0%), 55 (21.8%), 45 (17.9%), and 26 (10.3%) patients underwent gross total resection (GTR), subtotal resection, partial resection (PR), and biopsy, respectively. Their median overall survival (OS) was 20.8 months (95% confidence interval [CI] 17.7-23.9 months) and their median progression-free survival was 12.7 months (95% CI 11.2-14.2 months). The O 6-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 78 (34.1%) of the 229 patients assayed, and an isocitrate dehydrogenase 1 mutation was detected in 7 (6.6%) of the 106 patients analyzed. Univariate analyses showed that patient age, involvement of eloquent areas, involvement of the subventricular zone, presence of leptomeningeal seeding, Karnofsky Performance Status, extent of resection (EOR), MGMT promoter methylation, and presence of an oligodendroglioma component were prognostic of OS. Multivariate analysis showed that age, involvement of eloquent areas, presence of leptomeningeal seeding, EOR, and MGMT promoter methylation were significantly predictive of survival. OS in patients with GBM who undergo surgery followed by CCRT with TMZ is enhanced by complete resection. Other factors significantly prognostic of OS include that age, involvement of eloquent areas, presence of leptomeningeal seeding, and MGMT promoter methylation.

AB - The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution. Outcomes were retrospectively reviewed in 252 consecutive patients with newly diagnosed GBM who underwent surgery followed by CCRT with TMZ at the authors' institution between 2005 and 2013. At initial operation, 126 (50.0%), 55 (21.8%), 45 (17.9%), and 26 (10.3%) patients underwent gross total resection (GTR), subtotal resection, partial resection (PR), and biopsy, respectively. Their median overall survival (OS) was 20.8 months (95% confidence interval [CI] 17.7-23.9 months) and their median progression-free survival was 12.7 months (95% CI 11.2-14.2 months). The O 6-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 78 (34.1%) of the 229 patients assayed, and an isocitrate dehydrogenase 1 mutation was detected in 7 (6.6%) of the 106 patients analyzed. Univariate analyses showed that patient age, involvement of eloquent areas, involvement of the subventricular zone, presence of leptomeningeal seeding, Karnofsky Performance Status, extent of resection (EOR), MGMT promoter methylation, and presence of an oligodendroglioma component were prognostic of OS. Multivariate analysis showed that age, involvement of eloquent areas, presence of leptomeningeal seeding, EOR, and MGMT promoter methylation were significantly predictive of survival. OS in patients with GBM who undergo surgery followed by CCRT with TMZ is enhanced by complete resection. Other factors significantly prognostic of OS include that age, involvement of eloquent areas, presence of leptomeningeal seeding, and MGMT promoter methylation.

UR - http://www.scopus.com/inward/record.url?scp=85022045357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022045357&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000007422

DO - 10.1097/MD.0000000000007422

M3 - Article

C2 - 28682902

AN - SCOPUS:85022045357

VL - 96

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 27

M1 - e7422

ER -